Hepatitis C Treatment Eligibility and Comorbid Medical Illness in Methadone Maintenance (MMT) and Non-MMT Patients: A Case-Control Study
暂无分享,去创建一个
[1] Edward A Belongia,et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.
[2] D. Dieterich,et al. Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin , 2008, Alimentary pharmacology & therapeutics.
[3] G. Treisman,et al. Medical Consequences of Drug Abuse and Co-Occurring Infections , 2008, Substance abuse.
[4] J. Montaner,et al. A review of barriers and facilitators of HIV treatment among injection drug users , 2008, AIDS.
[5] D. Vlahov,et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] S. Kalichman. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. , 2008, Psychosomatic medicine.
[7] P. Halkitis,et al. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. , 2008, AIDS patient care and STDs.
[8] F. Vocci,et al. Clinical Management of Drug Addicts Infected with Human Immunodeficiency Virus and Hepatitis C Virus , 2008, Journal of addictive diseases.
[9] Z. Goodman. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. , 2007, Journal of hepatology.
[10] D. D. Des Jarlais,et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. , 2007, The International journal on drug policy.
[11] A. Butt,et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. , 2007, Journal of viral hepatitis.
[12] R. Stravitz,et al. Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 , 2007, The American Journal of Gastroenterology.
[13] Richard D Moore,et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic , 2006, AIDS.
[14] H. Conjeevaram,et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.
[15] E. Bini,et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non‐Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin * , 2006, Journal of viral hepatitis.
[16] C. B. Hare,et al. Comparison of characteristics of treated and non‐treated patients with Hepatitis C infection , 2006, Pharmacoepidemiology and drug safety.
[17] A. Alberti,et al. Review article: chronic hepatitis C – natural history and cofactors , 2005, Alimentary pharmacology & therapeutics.
[18] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[19] D. Sylvestre. Approaching treatment for hepatitis C virus infection in substance users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] F. Vocci,et al. Medical management of HIV-hepatitis C virus coinfection in injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] M. Fortin,et al. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. , 2005, Journal of clinical epidemiology.
[22] E. McCance-Katz,et al. Medical Illness and Comorbidities in Drug Users: Implications for Addiction Pharmacotherapy Treatment , 2005, Substance use & misuse.
[23] W. Wadland,et al. Medical comorbidity in addictive disorders. , 2004, The Psychiatric clinics of North America.
[24] W. Häuser,et al. Biopsychosocial Predictors of Health-Related Quality of Life in Patients With Chronic Hepatitis C , 2004, Psychosomatic medicine.
[25] A. Bulbena,et al. Medical Assessment in Drug Addicts: Reliability and Validity of the Cumulative Illness Rating Scale (Substance Abuse Version) , 2004, European Addiction Research.
[26] P. Killenberg,et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.
[27] B. Yawn,et al. Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat , 2004, The Annals of Family Medicine.
[28] Richard Saitz,et al. Burden of medical illness in drug- and alcohol-dependent persons without primary care. , 2004, The American journal on addictions.
[29] M. Busch,et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.
[30] J. Hoofnagle,et al. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 , 2002, Hepatology.
[31] J. Hoofnagle,et al. National institutes of health consensus development conference: Management of hepatitis C: 2002 , 2002 .
[32] D. Sylvestre. Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.
[33] K. Delucchi,et al. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. , 2002, Drug and alcohol dependence.
[34] A. McCullough,et al. Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C , 2002, Annals of Internal Medicine.
[35] B. Luxon,et al. Limited success of HCV antiviral therapy in United States veterans , 2002, American Journal of Gastroenterology.
[36] R. Fontana,et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C , 2001, American Journal of Gastroenterology.
[37] K. Seal,et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.
[38] G. Davis,et al. Treatment of chronic hepatitis C in active drug users. , 2001, The New England journal of medicine.
[39] M. Backmund,et al. Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.
[40] J. Henne,et al. The impact of homophobia, poverty, and racism on the mental health of gay and bisexual Latino men: findings from 3 US cities. , 2001, American journal of public health.
[41] Z. Goodman,et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.
[42] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[43] D. Vlahov,et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland , 1997, Journal of clinical microbiology.
[44] D. Vlahov,et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.
[45] J D Sapira,et al. The Medical Complications of Drug Addiction and the Medical Assessment of the Intravenous Drug User: 25 Years Later , 1993, Annals of Internal Medicine.
[46] Y. Conwell,et al. Validation of a Measure of Physical Illness Burden at Autopsy: The Cumulative Illness Rating Scale , 1993, Journal of the American Geriatrics Society.
[47] Sati Mazumdar,et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale , 1992, Psychiatry Research.
[48] B. Linn,et al. CUMULATIVE ILLNESS RATING SCALE , 1968, Journal of the American Geriatrics Society.
[49] T. Chalmers. American Association for the Study of Liver Diseases , 1959 .
[50] R. Grant,et al. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. , 2005, Journal of general internal medicine.
[51] D. Vlahov,et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. , 2001, American journal of public health.
[52] R H Purcell,et al. Clinical significance of hepatitis C virus genotypes and quasispecies. , 2000, Seminars in liver disease.
[53] P. Marcellin,et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.
[54] D. Vlahov,et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.